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a l umn ip r o f i l e
lbee Messing was always more interested in
human disease than animal disease. In fact, he
readily admits that he was somewhat
intimidated by any animal larger than a
mouse. So why did he end up at PennVet? Always a
researcher at heart, he recognized that Penn’sVeterinary
Medical ScientistTraining Program would provide him
with the best broad-based integrated training in medicine
to support the research he wanted to do in
neuropathology.
“Penn was a great place to study comparative
neuropathology with people like Nick Gonatas,MD,
professor, Department of Pathology and Laboratory
Medicine, at the medical school, and the late Jack
McGrath,V’43, at the veterinary school, who was one
of the leading neuropathologists of that generation,” notes
Dr.Messing, who received an undergraduate degree in
biology fromYale University.“The exceptional flexibility
of the combined degree program enabled me to focus on
neuropathology and develop it as my clinical specialty.”
After receiving his veterinary medicine degree summa
cum laude and completing his doctorate in experimental
pathology, Dr.Messing pursued a post-doctoral fellowship
in neuropathology with Dr. Gonatas. During this time, he
also began to collaborate with the laboratory of Ralph
Brinster,V’60, GR’64, Richard King Mellon Professor of
Reproductive Physiology at PennVet, on brain tumors and
peripheral nerve research involving transgenic models, a
collaboration he continued after accepting a position as
assistant professor of pathology at the University of
Wisconsin–Madison School of Veterinary Medicine
in 1985.
In his lab atWisconsin, Dr.Messing eventually shifted
the focus of his research to the central nervous system
when he began to study a gene that makes glial fibrillary
acidic protein (GFAP).This protein is found in the
astrocyte, a type of glial cell that supports and nourishes
neurons in the brain and spinal cord. If these nerve cells are
injured through trauma or disease, astrocytes react by
rapidly producing more GFAP. Through manipulation of
the GFAP gene expression, Dr.Messing made transgenic
mice, some with too much GFAP and some with none.
“We were curious about how this would affect astrocyte
function because scientists generally blamed astrocytes
for the inability to recover following a CNS injury,”
he explains.
Dr.Messing’s transgenic mice led to a breakthrough
discovery.“The mice with too much GFAP formed
abnormal aggregates of protein in the astrocytes called
Rosenthal fibers,” he relates.“That’s where the value of my
combined degree training became very apparent. I had
learned about Rosenthal fibers in diagnostic
neuropathology.You see them sporadically in a number of
diseases, but when you see them abundantly and
throughout the CNS, it’s really diagnostic of only one
disease in neuropathology—a rare disorder called
Alexander disease.”
Alexander disease, a leukodystrophy, is a progressive and
usually fatal neurological disorder in which the destruction
of white matter in the brain is accompanied by the
formation of Rosenthal fibers.The most common type of
Alexander disease is the infantile form, which typically has
an onset during the first two years of life. Usually there are
several types of developmental delays, both mental and
physical, followed by loss of milestones, an abnormal
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increase in head size, and seizures.The juvenile form,
which has an onset between ages 2 and 13, is less common,
and adult onset forms are even more rare.
“Alexander disease had been presumed as a genetic
disorder but no one had any clue what gene was
responsible for it,” explains Dr.Messing, who is now
faculty core director, Rodent Models Core, and professor,
comparative biosciences, at the University ofWisconsin’s
Waisman Center.“Because we had essentially recreated one
of the hallmark features of the disease simply by changing
expression of the GFAP gene, we put that forward as a
candidate for the gene responsible for the disorder.”
During the ensuing four years, Dr.Messing’s lab
assembled the world’s largest collection of Alexander
disease samples, and found that greater than 90 percent of
patients with the disorder have mutations in the GFAP
gene. For a time, his lab was the world resource for
genetic testing for Alexander disease.With such striking
results, the testing quickly moved from the lab into
standard clinical practice.
“I’m very gratified that we discovered something that’s
really made a contribution to this disorder and a difference
in people’s lives,” Dr.Messing reflects.“Alexander disease
takes over the world of these patients and their families.
Getting a clear diagnosis really matters to these parents.
Ultimately, we hope to develop a treatment, and we’ve
already started working toward that challenging goal.”
Going forward, Dr.Messing’s research may have
implications for a broader spectrum of neurologic and
neurodegenerative disorders, including epilepsy,Alzheimer’s
disease and Parkinson’s disease. “Astrocytes are increasingly
viewed by the scientific community as central players in a
variety of neurologic disorders,” he emphasizes.“We’d like
to learn how astrocyte dysfunction contributes to
Alzheimer’s and Parkinson’s, as well as Alexander disease,
and ultimately, how to modulate and possibly improve
astrocyte function and protect these cells from injury.”
a l umn ip r o f i l e
Penn Vet Alumnus Part of Major
Stem Cell Breakthrough
James Thomson,V’88, developmental biologistand anatomy professor at the University ofWisconsin–Madison, was part of a team of
researchers who discovered how to turn human
skin cells into what appear to be embryonic stem
cells without having
to create or destroy
an embryo.The







stem cells capable of
becoming any of the
220 cell types in the
human body.
In the new study—the results of which appear in
the December 21, 2007 issue of Science—Dr.
Thomson and his colleagues introduced a set of four
genes into human fibroblasts (skin cells easy to
obtain and grow in culture) to induce the skin cells
into a pluripotent state, a condition essentially the
same as that of embryonic stem cells. In addition to
eliminating ethical and political issues from the stem
cell debate, using reprogrammed skin cells allows for
customization to the patient.
“The induced cells do all the things embryonic
stem cells do,” explains Dr.Thomson.“It’s going to
completely change the field.”
Although Dr.Thomson is encouraged that the
new cells will speed up new cell-based therapies to
treat disease, more work is required, he says, to refine
the techniques through which the cells were gener-
ated to prevent incorporation of the introduced
genes into the genome of the cells. In addition, to
ensure their safety for therapy, methods to remove
the vectors—the viruses used to ferry the genes into
the skin cells—must be developed.
Dr.Thomson, who studied in the laboratory of
Dr. Ralph Brinster while at PennVet, also was the
first scientist to coax stem cells from human embryos
in 1998.
”
The exceptional flexibility of
the combined degree program
enabled me to focus on
neuropathology and develop
it as my clinical specialty.
“
